Core Viewpoint - Ontex has appointed Mr. Laurent Nielly as the new Chief Executive Officer, effective from May 5, 2026, succeeding Mr. Gustavo Calvo Paz, who has led the company through a strategic transformation [1][3]. Group 1: Leadership Transition - Mr. Laurent Nielly has been with Ontex since 2021 as President of the Europe Division, overseeing retailer brands and healthcare business across Europe [2]. - Nielly has over 25 years of experience in various regions and companies, including P&G, McKinsey & Company, PepsiCo, and Coty, with a background in finance, strategy, innovation, and commercial excellence [2]. - The Board of Directors expressed gratitude to Mr. Calvo Paz for his contributions, particularly in implementing strategic changes and optimizing Ontex's operations [3][4]. Group 2: Strategic Direction - Under Mr. Calvo Paz's leadership, Ontex focused on divesting non-core activities and optimizing its operational footprint, aiming to future-proof the organization with a focus on Europe and North America [3]. - The Board believes that Mr. Nielly is well-positioned to build on the accomplishments of his predecessor and accelerate value creation for Ontex [4]. Group 3: Company Overview - Ontex is a leading international developer and producer of baby care, feminine care, and adult care products, primarily serving retailers and healthcare sectors in Europe and North America [6]. - The company employs around 5,100 people and operates in 11 countries, with its products distributed in approximately 100 countries [6].

Core Insights - Progeny 3 increased its stake in TIC Solutions by 255,800 shares, raising its total position to 15.3 million shares valued at $203.1 million, making it the fund's second-largest holding [2][8] - TIC Solutions shares are currently priced at $9.42, reflecting a 27.5% decline over the past year, underperforming the S&P 500, which has increased by 12.5% in the same period [3][10] - The company is undergoing a significant rebranding and integration process following the Acuren-NV5 combination, with management emphasizing accelerating synergies and a larger operational platform [6][10] Company Overview - TIC Solutions, formerly known as Acuren, operates within the specialty business services segment, employing thousands and maintaining a strong presence in North America [5] - The company focuses on high-value, compliance-driven testing and engineering services, which are essential for clients' operational safety and regulatory compliance [5] - TIC Solutions is projected to achieve full-year service revenue between $1.53 billion and $1.565 billion for 2025, with adjusted EBITDA expected to be between $240 million and $250 million [9] Investment Perspective - Progeny 3's increased investment in TIC Solutions indicates confidence in the company's strategic transformation and potential for future growth [6][10] - TIC now represents 10.5% of Progeny 3's U.S. equity portfolio, highlighting its status as a high-conviction holding [8] - Despite the current stock performance, the market has not fully recognized the potential of TIC's combined platform, suggesting possible upside if management's projections for synergy capture and margin expansion are realized [10]

Core Insights - Vera Bradley, Inc. has appointed Ivan Brockman to its Board of Directors effective November 17, 2025, bringing extensive experience in strategic decision-making and investment banking [1][2]. Company Overview - Vera Bradley, based in Fort Wayne, Indiana, is a leading designer of women's handbags, luggage, travel items, fashion and home accessories, and unique gifts, known for its innovative designs and iconic patterns [5]. Leadership and Experience - Ivan Brockman has three decades of experience advising senior management teams and investors, currently serving as a Senior Advisor to PJT Partners and previously holding significant roles at Citigroup and Goldman Sachs [2][3]. - Throughout his career, Mr. Brockman has advised on over $100 billion of strategic transactions with major companies including Google, Microsoft, and Amazon [2]. Investment Activities - Mr. Brockman is also an active private investor in various sectors, including technology and consumer startups, with notable early-stage investments in companies like LifeLock and FIGS [3]. Strategic Transformation - Mr. Brockman expressed enthusiasm about joining Vera Bradley during a critical period of the company's strategic transformation [4]. Business Segments - Vera Bradley operates through two reportable segments: VB Direct, which includes sales through its own stores and websites, and VB Indirect, which consists of sales to specialty retail locations and other channels [6].

Core Insights - Shares of Palladyne AI Corp. (PDYN) have declined 17.5% since the earnings report for the quarter ended September 30, 2025, compared to a 1.9% decline in the S&P 500 index during the same period [1] - The company reported a third-quarter 2025 loss of 9 cents per share, an improvement from a loss of 27 cents per share in the same quarter of 2024 [1] - Revenue for the quarter was $0.9 million, reflecting a marginal year-over-year decline of 1.3% [1] Profitability Metrics - Palladyne incurred a net loss of $3.7 million, significantly narrower than the $7.1 million loss recorded in the year-ago quarter, driven by favorable warrant-related gains [2] - Total operating expenses rose to $8.9 million from $8.2 million a year ago, primarily due to a 21.8% increase in research and development (R&D) expenses, which reached $3.2 million [3] - Interest income more than doubled, contributing to improved bottom-line results, alongside a $3.8 million gain on warrant liabilities this quarter, compared to a loss of $0.04 million in the same period last year [3] Financial Position - The company ended the quarter with $57.1 million in cash, cash equivalents, and marketable securities, maintaining a debt-free balance sheet [4] - Operating cash usage was $6.3 million for the quarter, consistent with management's expectations [4] - Palladyne issued 8.2 million additional shares over the nine-month period, boosting its equity position from a deficit of $9.5 million at the end of 2024 to positive equity of $51.8 million as of September 30, 2025 [5] Strategic Developments - CEO Ben Wolff characterized the quarter as a "defining phase" for Palladyne, emphasizing alignment with evolving Department of War directives and the relevance of its closed-loop autonomy systems in national defense [6] - Management expressed confidence in the potential of strategic transformations through acquisitions and partnerships, particularly with GuideTech and Crucis, which are foundational to the newly branded "Palladyne Defense" unit [7] - Revenue stagnation was attributed to unchanged commercial traction for Palladyne IQ, which remains in limited deployment and internal testing phases [8] Research and Development - R&D expenses were elevated due to investments in next-generation capabilities and software upgrades, particularly for the upcoming release of Palladyne IQ [9] - CEO Ben Wolff acknowledged user interface challenges that have delayed the deployment of IQ V2, although internal testing is ongoing [9] Non-Operating Gains - The improvement in net income was significantly influenced by non-operating gains, particularly the $3.8 million gain on warrant liabilities, rather than core operational improvements [10] Other Developments - Palladyne was awarded U.S. Patent No. 12,452,957 for its closed-loop tasking and control architecture, aimed at enhancing the Palladyne Pilot platform [12] - The company expanded its collaboration with Draganfly to incorporate Palladyne Pilot into unmanned aerial vehicle (UAV) platforms, further embedding itself in defense applications [12] - Two acquisitions, GuideTech and Crucis, were finalized to accelerate product development cycles and integrate Palladyne's software across broader platforms under the newly established Palladyne Defense division [13]

Core Insights - NN, Inc. forecasts profitable sales growth and adjusted EBITDA growth in 2026, driven by strategic processes aimed at unlocking shareholder value [1][2][7] Financial Performance - Adjusted EBITDA for full year 2025 is expected to reach an annual record, marking a third consecutive year of growth in both dollar amount and as a percentage of sales [6] - Q4 2025 adjusted EBITDA and adjusted gross margins are projected to meet NN's five-year goals of 14% and 20%, respectively, more than two years ahead of schedule [6] - The company anticipates a year-over-year sales growth inflection for full-year 2026, with net sales growth expected in each fiscal quarter [6] Strategic Initiatives - NN is executing a focused set of strategic priorities to strengthen its balance sheet and enhance long-term competitiveness [6][7] - The company is progressing with a preferred equity refinancing initiative and plans to engage with the market soon [7] - NN has a successful M&A program in 2025, with several opportunities under evaluation, including transformational acquisitions to accelerate growth [6][7] Commercial Developments - NN's new business wins for full-year 2025 are expected to meet original guidance, contributing to solid year-over-year net sales growth and margin expansion [6] - The company has its largest sales growth team and opportunity pipeline, with over 800 new programs valued at more than $800 million annually [6] - NN maintains a hit rate of over 20% on closed opportunities, indicating strong commercial execution [6]

Financial Data and Key Metrics Changes - Adjusted net revenue was stable year over year at $5.5 billion, while adjusted EBITDA grew 15% to $3.2 billion, achieving a 59% margin [6][17] - Adjusted net income reached $1.2 billion, reflecting a 9.5% growth compared to the prior year, and cash flow from operations increased 22% to $1.7 billion [6][17] - EBITDA to cash conversion reached 54% in the quarter, indicating disciplined execution and resource optimization [6] Business Line Data and Key Metrics Changes - Water production increased by 4.4% year over year to 809 million cubic meters, with active connections growing by 0.6% [5] - Sewage connections rose by 1.1%, reflecting the company's investment focus on sewage services [5] Market Data and Key Metrics Changes - The company reported a collection efficiency of 101%, marking one of the highest historical performances [12][21] - The Fawuspi rate increased from 3.28% to 3.78%, impacting revenue and EBITDA [6][94] Company Strategy and Development Direction - The company is focused on three strategic priorities: delivering on the new concession agreement, improving operational efficiency, and strengthening financial efficiency [19][20] - CapEx accelerated to $4 billion in the quarter, growing 175% year over year, supporting the company's investment program [14][20] - The company is rolling out a large smart metering program, with 4.4 million IoT-enabled smart meters planned for installation by 2029 [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving universal access and improving service delivery, with a commitment to operational excellence and sustainable growth [17][19] - The company is optimistic about its ability to manage water security and has contingency plans in place for the upcoming rainy season [36][52] Other Important Information - The company has formalized a decarbonization roadmap with targets to reduce total emissions by 15% by 2035 [26] - The MI acquisition is expected to enhance water security and operational efficiency, with closing anticipated between late Q4 and early Q1 of the following year [27] Q&A Session Summary Question: Updates on the annual tariff review process - Management is in the final steps of determining the regulatory asset base addition for 2024 and expects to share updates soon [30][32] Question: Expectations on hydro resilience improvements - Short-term strategies include contingency plans for water management, while the MI acquisition is expected to enhance water security [36][39] Question: M&A opportunities and focus areas - The company is focused on fulfilling obligations from the privatization of Sabesp but is also exploring potential M&A opportunities as they arise [42][45] Question: Details on the severance program - The company does not expect to implement additional voluntary dismissal programs after the current one [48][50] Question: Impact of social tariffs on revenue - The impact of social tariffs in Q3 was approximately $117 million, which will be recovered through future tariff adjustments [59][65] Question: Discounts reduced for large clients - The total gain from discount removal for large clients in Q3 was approximately $133 million, with ongoing adjustments affecting pricing and mix [68][71] Question: CapEx execution details - The company executed $4 billion in CapEx, focusing primarily on sewage treatment and water safety improvements [102][105]

Core Insights - Solésence, Inc. is undergoing a strategic transformation aimed at enhancing innovation, product quality, and operational efficiency while expanding its market reach in skin care, sun care, and color cosmetics [3][6]. Financial Performance - Revenue for Q3 2025 was $14.5 million, a decrease from $16.9 million in Q3 2024, reflecting a year-over-year decline of approximately 14% [9]. - Gross margin for Q3 2025 was 23%, down from 36% in the same quarter of 2024, indicating a significant reduction in profitability [9]. - Gross profit for Q3 2025 was $3.4 million, compared to $6.1 million in Q3 2024, marking a decline of about 44% [9]. - The company reported a net loss of $1.1 million for Q3 2025, contrasting with a net income of $3.0 million in Q3 2024 [9]. Operational Highlights - The company has consolidated its manufacturing facilities from three to two, aiming to improve operational efficiencies [9]. - Recent structural changes include unifying R&D and Quality teams and increasing production automation to enhance productivity [6][9]. - The appointment of Laura Riffer as CFO and the promotion of Kevin Cureton to CEO are part of the leadership changes to support the company's strategic initiatives [8]. Strategic Initiatives - Solésence is focused on driving future innovation and growth through key leadership changes and operational restructuring [3][8]. - The company aims to solidify its position as a long-term partner for brand partners by delivering high-quality products efficiently [6].

Core Insights - Galapagos NV has concluded its strategic review process, deciding to wind down its cell therapy business to optimize capital allocation for a sustainable future [1][4] - The company has a robust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025, and expects to end the year with approximately €2.975 billion to €3.025 billion [1][15] - Leadership changes have been made to align with the new strategic direction, enhancing corporate and business development capabilities [3][6] Financial Performance - Total net revenues for the first nine months of 2025 reached €211.4 million, a 6% increase from €200.1 million in the same period of 2024 [5][9] - The company reported an operating loss of €462.2 million for the first nine months of 2025, significantly higher than the €125.6 million loss in the same period of 2024, primarily due to a €204.8 million impairment related to the cell therapy business [7][10] - Net loss from continuing operations was €463.0 million for the first nine months of 2025, compared to a net loss of €20.4 million for the same period in 2024 [10][12] Strategic Focus - The management aims to strategically deploy capital in a disciplined manner, focusing on value-accretive transactions, particularly in small molecule and biologics programs in immunology and oncology [1][4] - The company is actively evaluating opportunities and believes its partnership with Gilead provides a strategic advantage in pursuing these opportunities [1][4] Operational Changes - The wind down of the cell therapy business is expected to impact approximately 365 employees across various locations, with the remaining organization projected to consist of 35-40 employees by the end of 2026 [4][15] - The company anticipates being cash flow neutral to positive by the end of 2026, excluding any business development activities and currency fluctuations, if the wind down is successfully implemented [1][15] Clinical Pipeline - Galapagos is advancing its clinical pipeline, including GLPG5101, a CD19 CAR-T candidate in Phase 1/2 trials, and GLPG3667, a small molecule TYK2 inhibitor in Phase 3-enabling studies [5][6]

Core Insights - BayFirst Financial Corp. reported a significant net loss of $18.9 million, or $4.66 per share, for Q3 2025, compared to a net loss of $1.2 million in Q2 2025, primarily due to higher provision expenses and one-time charges related to restructuring [1][8][29] Financial Performance - The net interest margin decreased to 3.61% in Q3 2025 from 4.06% in Q2 2025, but increased from 3.34% in Q3 2024 [7][10] - Net interest income from continuing operations was $11.3 million in Q3 2025, down from $12.3 million in Q2 2025, but up from $9.4 million in Q3 2024 [10][11] - Noninterest income was negative $1.0 million in Q3 2025, a significant decrease from $10.8 million in Q2 2025 and $12.3 million in Q3 2024 [14][17] Strategic Initiatives - The company is undergoing a strategic transformation, including exiting the SBA 7(a) lending business and selling a portion of its loan portfolio to Banesco USA for 97% of the retained loans' balances, resulting in a net loss of $5.1 million [3][29] - Management is focused on derisking the balance sheet and enhancing long-term growth and shareholder value, with plans to close the SBA loan sale in Q4 2025 [3][4] Asset Quality - The provision for credit losses in Q3 2025 was $10.9 million, up from $7.3 million in Q2 2025 and $3.1 million in Q3 2024 [24] - The allowance for credit losses on loans was 2.61% of total loans held for investment as of September 30, 2025, compared to 1.65% in Q2 2025 and 1.48% in Q3 2024 [25] Balance Sheet Highlights - Total assets increased by $2.1 million, or 0.2%, to $1.35 billion in Q3 2025, driven by an increase in cash and cash equivalents [20] - Loans held for investment decreased by $127.1 million, or 11.3%, during Q3 2025, primarily due to the transfer of loans to held for sale [21] - Total deposits increased by $7.7 million, or 0.7%, during Q3 2025, totaling $1.17 billion [22] Capital and Liquidity - The Tier 1 leverage ratio was 6.64% as of September 30, 2025, down from 8.11% in Q2 2025 [27] - The bank's liquidity position remains strong, with an on-balance sheet liquidity ratio of 11.31% as of September 30, 2025 [28]

Core Viewpoint - Propetro Holding's stock price increased over 15% to $7.285 following the announcement of a long-term power supply agreement with a major cloud data center operator in the Midwest, marking a significant strategic milestone for the company [1] Group 1: Business Development - Propetro's PROPWR division will provide 60 megawatts of power to the data center through a hybrid solution consisting of natural gas generators and battery storage systems [1] - The agreement includes expansion and extension clauses, allowing for increased collaboration based on the customer's future energy demands [1] - The project is expected to commence deployment and operations in the second quarter of 2026 [1] Group 2: Strategic Importance - The partnership with a top-tier data infrastructure operator signifies a substantial commercial relationship for Propetro, reflecting the company's commitment to providing advanced and reliable energy solutions for data center infrastructure development [1]